24/7 Market News Snapshot 30 June, 2025 – Catheter Precision, Inc. (NYSE:VTAK)

June 30, 2025

DENVER, Colo., 30 June, 2025 (www.247marketnews.com) – (NYSE:VTAK) are discussed in this article.
Catheter Precision, Inc. has witnessed a significant boost in market performance, with its stock price rising approximately 10% to $0.261 after opening at $0.243. The surge signals positive investor sentiment, especially following a previous close at $0.237. The day’s trading volume has reached 5.48 million shares, indicating robust market interest that could influence further price movements. Analysts suggest that maintaining a price above $0.25 may allow the stock to test higher resistance levels soon, warranting close attention to its trading dynamics.

In tandem with its market performance, Catheter Precision has also announced the establishment of a transformative joint venture named Kardionav, focused on enhancing treatments for ventricular tachycardia (VT) through pioneering ablation technology. This new partnership brings together the skills of Catheter Precision and Chelak iECG, Inc., allowing both to leverage their intellectual properties and technical expertise in developing an advanced Ventricular mapping system.

Under the joint venture, Catheter Precision will retain a majority interest of about 56%, while Chelak iECG will hold 33%, with the remaining 10% allocated to management. Dr. Jie Cheng, the founder of Chelak iECG and a prominent figure in the field of cardiac electrophysiology, will take on the role of primary researcher. His extensive experience, particularly in integrating artificial intelligence for precise identification of ventricular arrhythmias, positions him to lead this initiative effectively.

David Jenkins, CEO of Catheter Precision, expressed enthusiasm about the venture, highlighting its intention to combine advanced imaging techniques and real-time conduction velocity calculations to enhance ablation outcomes. This collaboration aims to address existing treatment limitations for VT, ultimately improving the efficacy and safety of care provided to patients suffering from this condition. As Kardionav progresses, both companies are committed to transforming the landscape of cardiac electrophysiology and advancing patient care standards.

Related news for (VTAK)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.